DrugPatentWatch Database Preview

Details for Patent: 8,431,615

« Back to Dashboard

Which drugs does patent 8,431,615 protect, and when does it expire?

Patent 8,431,615 protects INCIVEK and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 8,431,615

Title:	Dose forms
Abstract:	The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Inventor(s):	Chu; Hui-May (Natick, MA), Ette; Ene (Framingham, MA), McNair; Lindsay (Allston, MA), Alam; John (Cambridge, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	11/264,746
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,431,615

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No						METHOD OF TREATING CHRONIC HEPATITIS C

International Family Members for US Patent 8,431,615

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005302361
Canada	2585647
China	101068547
China	102988365
European Patent Office	1819336
European Patent Office	2500021
Israel	182847